Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04735263 · ClinicalTrials.gov registry record · Phase 2
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
A Phase 2 study of Age-related Macular Degeneration, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT04735263 is a Phase 2 study of Age-related Macular Degeneration that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 21 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04735263, a Phase 2 study of Age-related Macular Degeneration, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT
Conditions Studied
Interventions
- DRUG Atorvastatin 80mg
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04735263
The ClinicalTrials.gov registry entry for NCT04735263 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin 80mg is the first listed.
NCT04735263 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04735263 about?
NCT04735263 is a clinical study titled "Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD". interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT
What is the current status of trial NCT04735263?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2021-02-04. Estimated completion is 2028-01-01.
What conditions does trial NCT04735263 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT04735263?
The interventions under investigation include: Atorvastatin 80mg (DRUG).
Who is sponsoring clinical trial NCT04735263?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04735263 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of RQC for AMD
COMPLETED · Phase 2
-
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
-
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.